MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Brivanib (alaninate)

CAS No. : 649735-63-7

MCE 站：Brivanib (alaninate)

产品活性：Brivanib alaninate (BMS-582664) 是一种 ATP 竞争性的 VEGFR2 抑制剂，IC₅₀ 值为 25 nM；可以适度抑制 VEGFR1 和 FGFR1，对 VEGFR2 的选择性是对 PDGFRβ 的 240 倍。

研究领域：Protein Tyrosine Kinase/RTK  |  Autophagy

作用靶点：VEGFR  |  Autophagy

In Vitro: Brivanib inhibits VEGFR1 ａnd FGFR-1 with IC₅₀ of 0.38 μM ａnd 0.148 μM. Brivanib is not sensitive to PDGFRβ, EGFR, LCK, PKCα or JAK-3 with IC₅₀ all above 1900 nM. Brivanib could inhibit the proliferation of VEGF-stimulated HUVECs with IC₅₀ of 40 nM, compared to 276 nM in FGF-stimulated HUVECs. On the other hand, brivanib exhibits low activity to tumor cell lines. Brivanib doses ≤20 µM paradoxically enhances FGF-induced LX-2 cell proliferation, whereas higher brivanib doses (≥30 µM) inhibits LX-2 cell proliferation. The inhibitory effect of brivanib on liver fibrosis is not through inhibition of TGF-β 1-induced stellate cell activation, ａnd is possibly through inhibition of PDGF-BB-induced stellate cell activation.

In Vivo: Brivanib displays antitumor activities in H3396 xenograft in athymic mice. At a dose of 60 ａnd 90 mg/kg (p.o.), brivanib completely inhibits the tumor growth, with TGI of 85% ａnd 97%, respectively. Moreover, brivanib significantly suppresses tumor growth in Hepatocellular carcinoma (HCC) xenografts, which due to the decrease in phosphorylation of VEGFR2. The results show that the tumor weights in 06-0606 xenograft mice are 55% ａnd 13%, compared with the controls at a dose of 50 mg/kg ａnd 100 mg/kg. Brivanib is suggested to be efficient in treatment of HCC. Brivanib (50 mg/kg, p.o.) attenuates liver fibrosis ａnd stellate cell activation induced by BDL in mice. Brivanib inhibits growth factor ａnd growth factor receptor mRNA expression in sham control animals but shows variable effects in bile duct ligated animals.

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Kinase Inhibitor Library  |  Protein Tyrosine Kinase Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Autophagy Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Differentiation Inducing Compound Library  |  Reprogramming Compound Library  |  Anti-Breast Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Bevacizumab  |  Sunitinib  |  Semaxinib  |  SU 5402  |  PD173074  |  5Z-7-Oxozeaenol  |  Cediranib  |  SAR131675  |  Gandotinib  |  PF-03814735  |  GW806742X  |  Tanshi IIA  |  Vatalanib dihydrochloride  |  CP-547632  |  Tyrphostin A9  |  AST 487  |  Ki20227  |  Motesanib  |  SU14813  |  Ramucirumab  |  SU1498  |  MAZ51  |  PP121  |  Ki8751  |  SU5408  |  ZM 306416

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。